Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Condition:   Triple Negative Breast Cancer (TNBC) Interventions:   Biological: spartalizumab;   Biological: LAG525;   Drug: NIR178;   Drug: capmatinib;   Biological: MCS110;   Biological: canakinumab Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials